Zilia, a Quebec City-based medical technology company specializing in non-invasive ocular biomarker assessment, has successfully closed a bridge financing round with participation from both existing and new investors, including Linearis Ventures. This infusion of capital is intended to support the commercialization of Zilia's flagship product, the Zilia Ocular—a retinal camera designed to measure oxygen saturation in the eye, facilitating early detection and management of ocular diseases such as glaucoma and diabetic retinopathy. The company's innovative platform, which integrates photonics and artificial intelligence, also holds potential applications in neurology, cardiology, and oncology. Linearis Ventures, a Montreal-based venture capital firm focused on AI and life sciences, has a history of investing in health technologies that combine artificial intelligence with biomarker discovery. The specific amount raised in this bridge round has not been publicly disclosed.